Reprogramming the immunological microenvironment through radiation and targeting Axl

Nature Communications

Volumn 7, Issue , 2016, Pages

  Aguilera, Todd A ^a   Rafat, Marjan ^a   Castellini, Laura ^a   Shehade, Hussein ^a   Kariolis, Mihalis S ^a   Hui, Angela Bik Yu ^b   Stehr, Henning ^a   Von Eyben, Rie ^a   Jiang, Dadi ^a   Ellies, Lesley G ^c   Koong, Albert C ^a,b   Diehn, Maximilian ^a,b   Rankin, Erinn B ^a,b   Graves, Edward E ^a,b   Giaccia, Amato J ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 6; PIMONIDAZOLE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE AXL; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS MIDDLE T ANTIGEN; AXL RECEPTOR TYROSINE KINASE; CYTOKINE; HLA ANTIGEN CLASS 1; ONCOPROTEIN;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; ENZYME; ENZYME ACTIVITY; GENETIC ANALYSIS; GROWTH; IMMUNITY; PROTEIN; SOLAR RADIATION; TUMOR;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WHOLE EXOME SEQUENCING; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL PROLIFERATION; ENZYMOLOGY; IMMUNITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION TOLERANCE; SECRETION (PROCESS); TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNITY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RADIATION TOLERANCE; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MICROENVIRONMENT;

EID: 85007079696     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13898     Document Type: Article

References (45)

1. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015).
2. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
3. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
4. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
5. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
6. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
7. Hiniker, S. M. et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5, 404-407 (2012).
8. Slovin, S. F. et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 24, 1813-1821 (2013).
9. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
10. Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A. & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365-372 (2013).
11. Grimaldi, A. M. et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3, e28780 (2014).
12. Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687-695 (2014).
13. Sharabi, A. B. et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345-355 (2015).
14. Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259-1271 (2006).
15. Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458-5468 (2014).
16. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015).
17. Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774-11779 (2014).
18. Finisguerra, V. et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522, 349-353 (2015).
19. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852-860 (2012).
20. Rankin, E. B. et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc. Natl Acad. Sci. USA 111, 13373-13378 (2014).
21. Graham, D. K., DeRyckere, D., Davies, K. D. & Earp, H. S. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14, 769-785 (2014).
22. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
23. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
24. Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. & Allison, J. P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717-1725 (2009).
25. Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379-5388 (2009).
26. Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007).
27. Sen, P. et al. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood 109, 653-660 (2007).
28. Camenisch, T. D., Koller, B. H., Earp, H. S. & Matsushima, G. K. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162, 3498-3503 (1999).
29. Pollack, B. P., Sapkota, B. & Cartee, T. V. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res. 17, 4400-4413 (2011).
30. Cline, M. S. et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci. Rep. 3, 2652 (2013).
31. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
32. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563-604 (2013).
33. Tiemessen, M. M. et al. CD4CD25Foxp3 regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446-19451 (2007).
34. Liu, G. et al. Phenotypic and functional switch of macrophages induced by regulatory CD4CD25 T cells in mice. Immunol. Cell Biol. 89, 130-142 (2011).
35. Kariolis, M. S. et al. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat. Chem. Biol. 10, 977-983 (2014).
36. Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010).
37. Sheridan, C. First Axl inhibitor enters clinical trials. Nat. Biotechnol. 31, 775-776 (2013).
38. Liu, L. et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res. 69, 6871-6878 (2009).
39. Zagorska, A., Traves, P. G., Lew, E. D., Dransfield, I. & Lemke, G. Diversification of TAM receptor tyrosine kinase function. Nat. Immunol. 15, 920-928 (2014).
40. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508-512 (2014).
41. Alciato, F., Sainaghi, P. P., Sola, D., Castello, L. & Avanzi, G. C. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J. Leukoc. Biol. 87, 869-875 (2010).
42. Paccez, J. D. et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32, 689-698 (2013).
43. Davie, S. A. et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 16, 193-201 (2007).
44. Bao, L., Cardiff, R. D., Steinbach, P., Messer, K. S. & Ellies, L. G. Multipotent luminal mammary cancer stem cells model tumor heterogeneity. Breast Cancer Res. 17, 137 (2015).
45. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).